Want to see JP:7679 full AI Analyst Report?
Top Page
Yakuodo Holdings Co., Ltd.
(7679)
Select Model
Select Model
Rating:61Neutral
Price Target:
¥1,614.00
▼(-25.52% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily held back by financial quality concerns—especially volatile and recently negative free cash flow and a sharp debt increase in 2026—despite steady revenue growth. Valuation is a meaningful positive with a low P/E and a dividend, while technical signals are mixed and do not strongly reinforce a bullish trend.
Positive Factors
Consistent Revenue Growth
A multi-year record of revenue growth indicates continued demand across the drugstore network and expanding sales capacity. Even with slower growth in 2026, sustained top-line progress can support store productivity, supplier scale, and ongoing investment over the next several quarters.
Negative Factors
Sharp Debt Increase
The recent debt step-up increases financial risk relative to the company’s earlier moderate leverage profile. Higher obligations can reduce flexibility for store investment and make earnings more sensitive to financing costs, leaving less capacity to absorb weaker trading or cash conversion.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
A multi-year record of revenue growth indicates continued demand across the drugstore network and expanding sales capacity. Even with slower growth in 2026, sustained top-line progress can support store productivity, supplier scale, and ongoing investment over the next several quarters.
Read all positive factors
Yakuodo Holdings Co., Ltd. (7679) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥30.40B
Dividend Yield1.9%
Average Volume (3M)57.97K
Price to Earnings (P/E)8.0
Beta (1Y)0.39
Revenue Growth8.08%
EPS Growth-15.52%
CountryJP
Employees1,094
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)200.86
Shares Outstanding19,740,220
10 Day Avg. Volume82,900
30 Day Avg. Volume57,973
Financial Highlights & Ratios
PEG Ratio-1.88
Price to Book (P/B)1.01
Price to Sales (P/S)0.25
P/FCF Ratio-4.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Yakuodo Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
YAKUODO HOLDINGS Co., Ltd., through its subsidiaries, engages in drugstore business in Japan. It retails health products, including energy drinks, cold medicine, disposable diapers for nursing care, and sanitary products; beauty products comprisin...
How the Company Makes Money
Yakuodo Holdings makes money mainly by selling products through its drugstore network. Its core revenue stream is retail sales, which typically include (1) pharmaceuticals (including prescription dispensing where store formats and regulatory licen...
Yakuodo Holdings Co., Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
62
Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 168.44B | 163.81B | 151.96B | 142.24B | 128.79B | 120.31B |
| Gross Profit | 32.47B | 31.71B | 29.66B | 27.86B | 25.45B | 24.65B |
| EBITDA | 9.04B | 8.97B | 8.71B | 8.16B | 7.56B | 6.66B |
| Net Income | 3.91B | 4.03B | 4.28B | 3.83B | 3.24B | 2.96B |
Balance Sheet | ||||||
| Total Assets | 104.88B | 103.17B | 80.26B | 71.07B | 68.01B | 62.59B |
| Cash, Cash Equivalents and Short-Term Investments | 6.87B | 10.01B | 7.17B | 4.95B | 5.28B | 4.25B |
| Total Debt | 26.61B | 34.60B | 18.19B | 13.60B | 15.75B | 15.61B |
| Total Liabilities | 64.22B | 62.94B | 43.19B | 37.75B | 38.06B | 35.05B |
| Stockholders Equity | 40.66B | 40.23B | 37.06B | 33.31B | 29.94B | 27.53B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -8.28B | 569.00M | 3.58B | 2.76B | -2.33B |
| Operating Cash Flow | 0.00 | 3.29B | 4.49B | 5.63B | 6.41B | 3.69B |
| Investing Cash Flow | 0.00 | -12.84B | -4.57B | -2.27B | -4.11B | -6.63B |
| Financing Cash Flow | 0.00 | 12.40B | 2.30B | -3.69B | -1.27B | -1.95B |
Yakuodo Holdings Co., Ltd. Technical Analysis
Negative
2167.00
Price Trends
1674.18
Negative
1681.24
Negative
1829.23
Negative
Market Momentum
-33.55
Positive
22.93
Positive
8.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7679, the sentiment is Negative. The current price of 2167 is above the 20-day moving average (MA) of 1617.55, above the 50-day MA of 1674.18, and above the 200-day MA of 1829.23, indicating a bearish trend. The MACD of -33.55 indicates Positive momentum. The RSI at 22.93 is Positive, neither overbought nor oversold. The STOCH value of 8.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7679.
Yakuodo Holdings Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥413.56B | 13.19 | 11.15% | 3.71% | 4.32% | 0.18% | |
69 Neutral | ¥503.63B | 15.73 | ― | 1.29% | 8.72% | 3.45% | |
64 Neutral | ¥938.68B | 16.67 | 7.13% | 2.20% | ― | ― | |
62 Neutral | ¥482.87B | 15.18 | 9.94% | 1.99% | 8.97% | -29.54% | |
61 Neutral | ¥30.40B | 8.00 | ― | 1.90% | 8.08% | -15.52% | |
56 Neutral | ¥393.55B | 20.65 | ― | 0.36% | 12.54% | 15.87% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
JP:7679
Yakuodo Holdings Co., Ltd.
1,530.00
-572.20
-27.22%
JP:9989
Sundrug Co
3,559.00
-452.06
-11.27%
JP:7649
Sugi Holdings Co
1,254.00
-398.34
-24.11%
JP:3391
TSURUHA Holdings
2,132.00
-259.07
-10.83%
JP:3349
COSMOS Pharmaceutical Corporation
6,359.00
-2,057.07
-24.44%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,116.00
440.98
12.00%
Yakuodo Holdings Co., Ltd. Corporate Events
Yakuodo grows sales but sees profit slide and leverage rise in first half
Oct 5, 2026
Yakuodo Holdings reported consolidated net sales of ¥89.76 billion for the six months ended August 31, 2026, an 8.4% year-on-year increase, but operating profit fell 5.3% to ¥3.29 billion and profit attributable to owners declined 11.8% ...
Yakuodo’s September Sales Stay Strong as Drugstore Chain Expands to 469 Stores
Oct 5, 2026
Yakuodo Holdings Co., Ltd. reported solid sales momentum for September 2026, with all-store net sales up 8.5% year on year and existing-store sales rising 3.1%. Growth was driven by both higher customer numbers and increased average spending, exte...
Yakuodo’s August Flash Report Shows Solid Sales and Ongoing Regional Expansion
Sep 4, 2026
Yakuodo Holdings reported that all-store net sales for March through August of the fiscal year ending February 28, 2027 rose between 2.9% and 12.5% year on year, supported by growth in both customer numbers and average spending. Existing stores al...
Yakuodo Holdings Posts July Sales Gain as Store Network Expands to 468 Locations
Aug 5, 2026
Yakuodo Holdings reported solid year-on-year growth in July 2026, with net sales up 4.9 percent at all stores and 2.9 percent at existing stores, driven by increases in both customer numbers and average spend. The figures, presented as flash data,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.